<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359917</url>
  </required_header>
  <id_info>
    <org_study_id>REC06/MRE00/39</org_study_id>
    <nct_id>NCT01359917</nct_id>
  </id_info>
  <brief_title>Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome</brief_title>
  <official_title>Psychological Morbidity and Facial Volume in HIV Lipodystrophy:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Lothian</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypotheses of this study were that:

        1. HIV lipodystrophy is associated with psychological morbidity relating to body image,
           anxiety and depression.

        2. Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or
           Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical
           volume of treated areas.

        3. The DI3D system is a valid and reproducible method of recording and measuring facial 3-D
           volume.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      as above
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of 3-D facial volume</measure>
    <time_frame>2 years</time_frame>
    <description>3-D facial camera</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>psychological outcome</measure>
    <time_frame>2 years</time_frame>
    <description>derriford appearance scale hospital anxiety and depression scale</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <arm_group>
    <arm_group_label>autologous fat transfer</arm_group_label>
    <description>patients received fat transfer for HIV lipodystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>polylactic acid</arm_group_label>
    <description>treatment with polylactic acid (PLA) for HIV lipodystrophy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bio-alcamid</arm_group_label>
    <description>bio-alcamid injections</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        50 patients with HIV facial lipoatrophy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV facial lipoatrophy

          -  concurrent antiretrovirals

        Exclusion Criteria:

          -  known psychological disorder

          -  skin allergies

          -  significant medical problems precluding anaesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth J Stewart, FRCSPlast</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Lothian</affiliation>
  </overall_official>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Lisa Nelson</name_title>
    <organization>NHS Lothian</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

